Condition: Delayed Platelet Engraftment · Neuroblastoma · Autologous Hematopoietic Stem Cell Transplantation · Sponsor: Beijing Children's Hospital
The goal of this clinical trial is to learn if hetrombopag promotes platelet engraftment in neuroblastoma children undergoing autologous hematopoietic stem cell transplantation. The main question it aims to answer is: · Does drug hetrombopag promote platelet engraftment? Participants will take hetrombopag every day for 6 weeks or until platelet \> 100\*10\^9/L.
This description comes directly from the study's public registry record.
Dr. Yang · 86-010-59617614 · yangjundabby@outlook.com
Always discuss trial participation with your own doctor first.
| Department of Stem Cell Transplantation, Beijing Children's Hospital, Capital Medical University | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06818916